BioCryst Pharmaceuticals News

With 80% Ownership, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Boasts of Strong Institutional Backing

Yahoo FinanceApr 22 08:04 ET

BioCryst to Report First Quarter 2024 Financial Results on May 6

RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2024 financial results on Monday, May 6,

GlobeNewswireApr 22 07:00 ET

FYBR, BCRX and SABR Are Among After Hour Movers

Seeking AlphaApr 18 16:56 ET

Express News | BioCryst Pharmaceuticals Announced That The Brazilian Health Regulatory Agency Has Granted Approval For Oral, Once-daily ORLADEYO (Berotralstat) For The Prophylaxis Of Hereditary Angioedema (Hae) Attacks In Adults And Pediatric Patients 12 Years

Moomoo 24/7Apr 17 04:36 ET

Express News | BioCryst Announces Approval of Orladeyo® (Berotralstat) by the Brazilian Health Regulatory Agency

Moomoo 24/7Apr 17 04:30 ET

Express News | Needham Reiterates Buy on BioCryst Pharma, Maintains $12 Price Target

Moomoo 24/7Apr 10 07:10 ET

BioCryst Pharma Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 04/10/2024 147.42% Needham → $12 Reiterates Buy → Buy 01/08/2024 147.42% Needham → $12 Reiterates Buy → Bu

BenzingaApr 10 07:08 ET

Why Investors Shouldn't Be Surprised By BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Low P/S

With a price-to-sales (or "P/S") ratio of 2.9x BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) may be sending very bullish signals at the moment, given that almost half of all the Biotechs companies in t

Simply Wall StApr 8 13:31 ET

BioCryst to Present at Upcoming Investor Conferences

RESEARCH TRIANGLE PARK, N.C., March 25, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the H.C. Wainwright 2nd Annual Autoimmune &

GlobeNewswireMar 25 16:01 ET

13 Best Biotech Stocks To Buy Under $20

Yahoo FinanceMar 13 07:07 ET

Institutional Owners May Take Dramatic Actions as BioCryst Pharmaceuticals, Inc.'s (NASDAQ:BCRX) Recent 5.0% Drop Adds to One-year Losses

Key Insights Given the large stake in the stock by institutions, BioCryst Pharmaceuticals' stock price might be vulnerable to their trading decisions A total of 13 investors have a majority stake in

Simply Wall StMar 13 07:01 ET

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

RESEARCH TRIANGLE PARK, N.C., March 05, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired

GlobeNewswireMar 5 07:01 ET

New Regulation Risk for BioCryst Pharmaceuticals – What's the Latest?

TipRanksFeb 29 01:00 ET

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Q4 2023 Earnings Call Transcript

Yahoo FinanceFeb 28 10:47 ET

BioCryst Pharmaceuticals Files for a Mixed Securities Shelf

Seeking AlphaFeb 27 17:15 ET

BioCryst Pharmaceuticals Full Year 2023 Earnings: EPS Misses Expectations

Yahoo FinanceFeb 27 05:07 ET

Q4 2023 BioCryst Pharmaceuticals Inc Earnings Call

Yahoo FinanceFeb 27 04:05 ET

What's Going On With BioCryst Stock After Earnings?

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares are flat Monday after the company reported its fourth-quarter financial results before the opening bell.The Details:BioCryst reported quarterly loss

BenzingaFeb 26 13:30 ET

10 Health Care Stocks With Whale Alerts In Today's Session

Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth.

BenzingaFeb 26 12:35 ET

Earnings Call Summary | BioCryst Pharmaceuticals(BCRX.US) Q4 2023 Earnings Conference

The following is a summary of the BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2023 Earnings Call Transcript:Financial Performance:BioCryst Pharmaceuticals reported a total revenue of $326 million in 2023

moomoo AIFeb 26 11:58 ET · Conference Call